United States Axial Spondyloarthritis (axSpA) Epidemiology Research Report 2021-2030 - ResearchAndMarkets.com

The "Axial Spondyloarthritis (axSpA) - United States Epidemiology Insight - 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Axial Spondyloarthritis (AxSpA) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the axSpA, historical and forecasted epidemiology as well as the axSpA trends in the United States.

Axial Spondyloarthritis (axSpA) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Axial Spondyloarthritis, Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis scenario in the United States, from 2018 to 2030.

Axial Spondyloarthritis (axSpA) Detailed Epidemiology Segmentation

• The total prevalent population of Axial Spondyloarthritis (axSpA) in the US was estimated to be 3,122,331 in 2020 which is anticipated to rise till 2030. Out of the total prevalent population, 1,336,050 cases were diagnosed in 2020.
• In the epidemiology model, different age-groups are included, i.e., 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 70+ years. It is estimated that the most prevalent age-group for axSpA in the United States was 40-49 years in 2020.
• The total prevalent population of nr-axSpA and AS in the US was estimated to be 1,821,360 and 1,300,971 in 2020, respectively.
• In 2020, out of the total diagnosed cases of nr-axSpA, 670,252 cases had HLA-B27 gene mutation, and 109,111 cases involved other genes (ERAP 1, IL-12, IL-17, and IL-23). Additionally, in cases of AS, out of the total diagnosed cases in 2020, 501,019 cases involved HLA-B27 gene, and 55,669 cases had other genes involvement.
• The prevalent population of AS showed a male predominance, whereas nr-axSpA showed a female predominance. Out of the total diagnosed population of nr-axSpA 779,363 cases in the US, 335,126 and 444,237 cases were contributed by males and females, respectively, in 2020.

Scope of the Report

The diagnosis of axial spondyloarthritis (axSpA) can be tough to spot as so many people have back pain - its main symptom. Additionally, there are no specific lab tests to identify the condition. All these factors play a major role in the low diagnosis of axSpA. Gender difference in both the types of axSpA has shown different trend. In case of nr-axSpA, female dominance is observed, whereas in AS, male dominance is there.

• The report covers the descriptive overview of AXSPA, explaining its causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the historical and forecasted patient pool covering the United States.
• The report assesses the disease risk and burden and highlights the unmet needs of AXSPA.
• The report helps to recognize the growth opportunities in the United States with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for the United States by Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis.

Report Highlights

• 10-Year Forecast of axSpA
• United States Coverage
• Total Prevalent Cases of Axial Spondyloarthritis
• Total Diagnosed Prevalent Cases of Axial Spondyloarthritis
• Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
• Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
• Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis

Key Questions Answered

• What are the disease risk, and burden of axSpA?
• What is the historical axSpA patient pool in the United States?
• What would be the forecasted patient pool of axSpA at the United States level?
• What will be the growth opportunities across the United States with respect to the patient population pertaining to axSpA?
• Out of the above-mentioned countries, which country would have the highest prevalent population of axSpA during the forecast period (2021-2030)?
• At what CAGR the population is expected to grow across the United States during the forecast period (2021-2030)?

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Executive Summary of Axial Spondyloarthritis (axSpA)

4 Disease Background and Overview

4.1 Introduction

4.2 Cause

4.3 Etiology

4.3.1 Endogenous Factors

4.3.2 Exogenous Factors

4.4 Risk Factors

4.4.1 Gender

4.4.2 Family History

4.4.3 Genetic Predisposition

4.4.4 Age

4.5 Signs and symptoms

4.6 Genetics - an insight into the pathogenesis

4.6.1 HLAB27 causing AS

4.6.2 Antigen processing and presentation

4.6.3 IL-17 and type 3 immunity in AS

4.6.4 IL-17

4.6.5 IL-23 signaling

4.6.6 Targeting type-3 immunity in AS

4.7 Biomarkers

4.7.1 Genetic biomarkers

4.7.2 Markers for inflammation

4.7.3 Cartilage Turnover Markers

4.7.4 Other Biomarkers

4.8 Clinical Manifestations

4.8.1 Peripheral arthritis

4.8.2 Enthesitis

4.8.3 Restriction of spinal mobility

4.8.4 Hip and shoulder joints

4.8.5 Dactylitis

4.8.6 Extra-articular locations

4.9 Diagnosis

4.9.1 Blood tests

4.9.2 Imaging tests

4.10 Differential Diagnosis

4.11 Underdiagnoses and Diagnostic Delay

4.12 Diagnostic Criteria

4.13 New York Classification Criteria: Diagnostic Criteria for AS

5 Epidemiology and Patient Population

5.1 Methodology

5.2 United States

5.2.1 Assumptions and Rationale

5.2.2 Total Prevalent Cases of Axial Spondyloarthritis in the United States

5.2.3 Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

5.2.4 Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

5.2.5 Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

5.2.6 Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/a49w1m

View source version on businesswire.com: https://www.businesswire.com/news/home/20211125006100/en/